Chondroitin and glucosamine sulphate reduced proinflammatory molecules in the DRG and improved axonal function of injured sciatic nerve of rats

• Published in: Scientific reports 2022-02, Vol.12 (1), p.3196-3196, Article 3196
• Main Authors: Olaseinde, Olutayo Folajimi, Owoyele, Bamidele Victor
• Format: Article
• Language: English
• Subjects: 631/337; 631/378; 631/443; 631/45; 692/698; 692/699; Analgesics; Animals; Chondroitin - therapeutic use; Chronic Pain - drug therapy; Constriction; Disease Models, Animal; Dorsal root ganglia; Drug Synergism; Drug Therapy, Combination; Drugs; Ganglia, Spinal - drug effects; Glucosamine; Glucosamine - therapeutic use; Histopathology; Humanities and Social Sciences; Hyperalgesia; Immunohistochemistry; Immunomodulation; Inflammation; Inflammation - drug therapy; Male; multidisciplinary; Nervous system; Neuralgia - drug therapy; Neuromodulation; Neuropathy; Oral administration; Pain; Pain perception; Quality of life; Rats; Rats, Wistar; Sciatic nerve; Sciatic Nerve - drug effects; Sciatic Nerve - injuries; Science; Science (multidisciplinary); Side effects; Sulfates
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-06554-4

Neuropathic pain (NP) is an abnormality resulting from lesion or damage to parts of the somatosensory nervous system. It is linked to defective quality of life and often poorly managed. Due to the limited number of approved drugs, limited efficacy and side effects associated with the approved drugs, drugs or drug combinations with great efficacy and very minimal or no side effects will be of great advantage in managing NP. This study aimed at investigating the synergistic antinociceptive effects of the combination of glucosamine sulphate (GS) (240 mg/kg) and chondroitin sulphate (CS) (900 mg/kg) in chronic constriction injury (CCI)-induced neuropathy in rats. Forty-two Wistar rats were randomly distributed into seven groups (n = 6). Sciatic nerve was ligated with four loose ligatures to induce NP. Effects of drugs were examined on stimulus and non-stimulus evoked potentials, expression of dorsal root ganglia (DRG) pain modulators and structural architecture of DRG. Oral administration of GS and CS for 21 days reduced hyperalgesia, allodynia, sciatic nerve functional aberration and DRG pain modulators. Histopathology and immunohistochemistry revealed restoration of structural integrity of DRG. Our result showed that the combination of GS and CS produced antinociceptive effects by attenuating hyperalgesia, allodynia and downregulation of NP mediators. GS and CS additionally produced synergistic analgesic effect over its individual components.